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                               INTRODUCTION     
 
                            
                                Gestational Diabetes Mellitus is defined as carbohydrate  
 
intolerance of variable severity with onset or first recognition during pregnancy,  
 
according to WHO guidelines. 
 
 
                                Gestational  Diabetes Mellitus is “ any degree of glucose  
 
intolerance that either starts during pregnancy or is newly diagnosed in pregnancy”  as 
  
per ACOG (American College of. Obsterics and Gynecology) 
 
                               It includes women, whose glucose tolerance, is normal after 
 
 pregnancy and those with type 2 diabetes with persistent glucose intolerance  
 
developed later 
                        
                           The GDM incidence is nowadays increasing due to life style changes, 
  
increased obesity and metabolic syndrome prevalence. The trend towards modern life 
 
 style, older age at child birth, changing eating habits and reduced physical activity has 
 
 now lead to increased GDM incidence. History of diabetes in family (like father, 
 
 mother, maternal uncle and aunts, and in siblings too) 
 
                            In addition to all above factors, ethnicity also plays a role in the 
development and risk of GDM. Our Indian ethnicity is more prone for developing 
Diabetes in the Gestational period. Moreover as India is in the trend towards adoption  
of western life sytle among youngsters , this risk factor adds an additional impact of   
health in the development 
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             The incidence of GDM is increasing globally and is now 20% to 27% of all  
 
pregnancies. According to Indian diabetic federation, in 2015, two out of every five  
 
diabetic women,  are of reproductive age, accounting for women over 60 million  
 
worldwide. According to this estimate, 16.2% of live births, who delivered in 2015  
 
had some form of .,hyperglycemia in pregnancy. In that, GDM accounted for  
 
85.1%.Gestational diabetes affects one in seven births. For a successful pregnancy  
 
outcome, the longitudinal changes, that takes place, in carbohydrate metabolism  
 
during pregnancy plays an integral role. 
 
 
               Gestational diabetes mellitus is an important cause of perinatal mortality and  
 
morbidity. The complications occurring due to GDM are preventable if screening and  
 
diagnosis is done at an early stage as possible 
 
MATERNAL COMPLICATIONS: 
 
 Polyhydramnios 
 
 Infections 
 
 Risk of preeclampsia 
 
 Ketoacidosis 
 
 Worsening of nephropathy and retinopathy in cases of pre existing diabetes 
 
 Maternal distress due to polyhydramnios 
 
 Preterm labour 
 
  Labour complications like increased birth trauma, shoulder dystocia due to  
 
big baby, increased instrumental deliveries, risk of postpartum hemorrhage,  
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operative interference 
 
 Puerperal complications like sepsis and lactation failure 
 
FETAL COMPLICATIONS: 
 
 Macrosomia 
 
 Respiratory distress 
 
 Intra-uterine growth restriction 
 
 Intra-uterine fetal demise 
 
 Congenital malformations ( if diabetic in organogenesis period) 
 
NEONATAL COMPLICATIONS: 
 Hypoglycemia 
 
 Respiratory distress syndrome 
 
 Hyperbilirubinemia 
 
 Polycythemia 
 
 Hypocalcemia 
 
 Hypomagnesemia 
 
 Cardiomyopathy 
 
LONG-TERM  EFFECTS : 
 
 Childhood obesity 
 
 Neuropsychological effects 
 
 Risk of type 2 DM  
 
 Risk of metabolic syndrome 
 
 
              The complications arising in GDM is mostly preventable if adequate control  
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of  blood sugar levels are maintained throughout the pregnancy. As it is always  
 
good  that PREVENTION IS BETTER THAN CURE, it is better to stop from  
 
happening  bad than it is to deal with it after it has happened. Gestational  
 
diabetes poses short term as well as long-term effects on the health of both the  
 
mother and the child. Hence early diagnosis and treatment is necessary to  
 
decrease the risks. 
 
                            High frequency of GDM among Indian women needs early diagnosis 
 
of  GDM. There is no specific biochemical test so far available that can  
 
predict  the  risk of developing GDM other than the blood sugar tests  
 
with  OGCT, OGTT etc. Recent studies have shown a positive correlation  
 
between  moderately elevated serum ferritin levels in mid trimester of  
 
pregnancy and increased risk of GDM. 
 
                    Insulin resistance plays a key role in GDM and there is a systemic  
 
inflammation,   indicated by higher levels of C-reactive protein   &   
 
interleukin-6. Adipocytes in adipose tissue can secrete pro inflammatory  
 
cytokines in obesity which is also associated with insulin resistance. 
 
serum ferritin , is a major storage protein of iron. It is also a acute phase  
 
reactant which increases in inflammatory conditions . Studies have shown a  
 
positive relation between insulin resistance and serum ferritin levels. 
 
                  The role of serum ferritin as an inflammatory marker is used in this  
 
study and its levels are measured in mid pregnancy to predict the risk of  
 
developing GDM, thereby making it as a tool for early diagnosis and  
 
prevention.  
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          REVIEW OF LITERATURE 
 
GESTATIONAL DIABETES MELLITUS 
 
                    GDM is defined as any degree of. glucose intolerance with onset or first 
 
recognition during pregnancy (WHO, ACOG).(1) 
 
                    It includes women whose glucose tolerance  returns back to 
 
normal after pregnancy and those who will develop type 2 diabetes , with 
 
persistent  glucose intolerance. 
 
INCIDENCE OF GDM: 
 
                   According to., Metzer Et al GDM is found in forty to sixty percent of 
 
women.  Incidence is increasing, that reflects the prevalence of  obesity and metabolic  
syndrome .  
 
The following are the risk factors for developing GDM 
 
 Modern life style and stress 
 
 older age at child birth,  
 
 Changing eating habits  
 
 Reduced physical activity  
 
 Family history of diabetes 
 
 Past history of GDM 
 
  Ethnicity 
 
 PCOS 
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CARBOHYDRATE METABOLISM IN PREGNANCY: 
                      
                  Pregnancy is a state of unique physiological condition.  It is a  
diabetogenic state with increase in insulin resistance progressively.(2) 
 Insulin resistance:  
            Human Placental Lactogen,  oestrogen, Progestrone, Cortisol…, all have        
                anti-insulin action. Also prolactin, tumour necrosis factor-a, C-reactive  
                protein, Interleukin-6 are a cause for insulin resistance. 
           Increased destruction of Insulin by Kidney and Placenta (Insulinase) 
 Increased lipolysis: 
 
Glucose sparing for fetus by utilisation of fatty acids for caloric needs by  
 
    Mother 
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 Gluconeogenesis changes: 
 
Major gluconeogenic sources like alanine and other amino acids is used by  
               fetus preferentially  (3)       
           Accelerated starvation of pregnancy:  Maternal amino acids and FFA  
               utilised as substrate for glucose, causing a state of mild ketosis. 
 Increased  post- prandial glucose: 
 
due to increased insulin resistance, lack of glucagon inhibition and increased  
 
placental diabetogenic hormones., which leads to diabetogenic state.(4) 
 
 Tendency for. fasting hypoglycaemia: 
 
Fetus utilises glucose continuously, irrespective of glucose levels in mother.,  
 
    even in a state of starvation. 
 
 Increased hepatic glucose output. 
 
 Exaggerated insulin secretion, in response to glucose 
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                         In early pregnancy , there is insulin sensitivity, but in second and third  
trimester there will be insulin resistance  to provide more glucose to the fetus. Basal 
 insulin secretion and postprandial insulin secretion increases progressively in  
advancing gestation, which reaches almost twice the non-pregnant level seen in third  
trimester.  At the same time there develops more insuin resistance, peaking at around  
34-36 weeks 
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FETAL GLUCOSE HOMEOSTASIS: 
                          
                          Entry of glucose, into the placenta occurs by facilitated transport. 
The fetal glucose levels and maternal glucose levels remain same with a maximum  
difference of 10mg/dl lower in fetus than the mother glucose levels.(5) 
  
                           
                            Maternal insulin will not cross placenta. Fetus starts produce insulin  
From late first trimester onwards. But more significant importance of fetal insulin is  
that it helps in fetal growth, than in controlling blood sugar. 
                          
                           When maternal blood glucose levels exceed 200mg/dl, the facilitated  
glucose diffusion from placenta to fetus is blocked as a natural mechanism. At this  
moment the fetal insulin secretion becomes more brisk and recognises the need to  
maintain its own glucose homeostasis.   
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                         The theory  of.,  “HYPERGLYCEMIC HYPERINSULINEMIA”  was  
postulated by Pederson. (6) .In this theory, it is said that hyperglycemia of the mother 
leads to hyperglycemia of the fetus, which in turn stimulates fetal pancreas to secrete  
more insulin by hypertrophy of  pancreatic B-cells. This hyperinsulinemia in the fetus 
leads to increased deposition of  fat and then macrosomia, increased production of  
erythropoietin and decreased production of surfactant. This is the cause of increased  
risk of birth trauma, intrapartum asphyxia, polycythemia and respiratory distress. 
 
EFFECT OF DIABETES ON THE MOTHER: 
                    
                    Geatational diabetes is similar to type 2 diabetes in the aspect of insulin  
resitance, with normal or increased levels of insulin. Pregnancy hormones, which are  
mostly diabetogenic likely aggrevate the diabetic condition or it may even bring out of  
latency, as may be seen in gestational diabetes. So after delivery, it may or may not  
revert back to normal in some women. Women with GDM do not have risk of  
13 
 
congenital malformations, spontaneous abortions or nephropathy or retinopathy as 
seen in women with type 2 diabetes, though other risk of pregnancy complication are  
high like preeclampsia, hydramnios or preterm or stillbirth. 
 
 
 
 
               
                    Maternal hyperglycemia in pregnancy has an increased risk of developing  
type 2 diabetes in the future. Based on this concept, a systemic review was analysed  
and then addressed as follows. 
 Cumulative incidence, of type2 diabetes markedly increased in first 5 years. 
 
 Incidence then plateaued in next 10 years. 
 
 Fasting hyperglycemia determines the risk of type 2 diabetes in future 
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EFFECT OF DIABETES ON  THE FETUS: 
            The prognosis of the fetus depends on the adequate glycemic control status. 
Gestational diabetes, has increased risk of macrosomia, preeclampsia, preterm births  
birth injuries and perinatal mortality and perinatal morbididty. 
 
 MACROSOMIA : 
 
Large for date baby ( BW>90TH percentile or >2SD for GA) 
 
Look edematous and bloated and often mistaken as postmature baby (7) 
 
Hallmark of poorly controlled diabetes 
 
Used as measure of outcome of diabetic pregnancy. 
 
Excluded in case of maternal high BMI and ethnic inheritance. 
 
Significant correlation with fasting blood glucose levels 
 
Reduction in incidence seen if adequate control of glucose levels maintained 
 
Increased risk of intrauterine fetal demise seen in macrosomic babies. 
 
Bartha et al reported, early GDM group are at risk of all kinds of perinatal  
 
    and intrapartum complications 
 
 
 
 STILLBIRTH: 
 
Increased risk of still birth is associated with fasting hyperglycemia. 
Fasting hyperglycemia>105mg/dl poses risk of IUFD in last 4 to 8 weeks of  
     pregnancy 
Mean glucose levels have linear correlation with stillbirth. 
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Chronic hypoxia is the key pathway of IUFD 
Maternal hyperglycemia which produces hyperinsulinemia is the basis of   
    chronic hypoxia 
Hyperinsulinemia causes increased oxygen consumption and arterial  
    oxygenation decrease. 
Erythropioetin production in response to chronic hypoxia is well observed in  
    the fetus as well as the amniotic fluid. 
In cases of still birth, if the amniotic fluids were checked for erythropoietin 
    levels, positive results were observed in diabetic women with high levels of  
    erythropoietin. 
These factors may also cause serious cardiac dysfunction in the fetus. 
This has been proved by a cohort study by Russell et al as the presence of  
    cardiomyopathy and high troponin –T levels in cord blood of type 1  
    diabetics, which is a valuable indicator of myocardial ischemia in the fetus,  
    which has caused stillbirth in 40% of study population 
 
 
 PRETERM LABOUR: 
 
Recent large cohort study by Hedderson et al, with 46,000 women, with  
 
   screening for GDM wasdone at 24-28 weeks, by carpenter cousten criteria. 
 
Risk of preterm birth was higher by 70%in women with screening positive      
 
    for GDM by the same criteria 
 
This association, is anyway independent from other factors causing preterm  
 
    Labour. 
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 SPONTANEOUS ABORTIONS AND CONGENITAL  
 
MALFORMATIONS:   
 
Risk is higher in pre-diabetics than GDM mothers. 
 
Risk correlates with HbA1C levels at the time of conception and during the  
 
    period of organogenesis  
 
    -Levels<6.5% is safe in pregnancy. 
 
    -Levels >9.5% - risk is 28% 
 
Common congenital malformations are cardiac and neural tube defects. 
 
Cardiac defects include VSD, TGA, TOF, hypoplastic left heart. 
 
NTD includes spina bifida, anencephaly, caudal regression etc. 
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EFFECT OF DIABETES ON THE NEONATE:      
 
 NEONATAL HYPOGLYCEMIA: 
            Occurs immediately after birth 
            Cause is fetal hyperinsulinemia 
           Seen in 30-50% of neonates born to diabetic mother. 
           Defined as blood glucose value less than as 30-40mg/dl , at term,  
               in the first 12 hrs after birth. 
           More risk in preterms 
           Adequate control in last trimester may decrease the risk 
 
 
 NEONATAL HYPERBILIRUBINEMIA:     
 
Manifests from second day of  birth 
 
Associated with maternal glycemic levels in pregnancy 
 
Linked with prematurity, bilirubin conjugation system immaturity 
 
Birth trauma is also a contributor 
 
 
 RESPIRATORY DISTRESS SYNDROME:     
 
Lung maturity is delayed in poor glycemic control. 
 
Risk decreases if pregnancy prolonged upto 38 weeks. 
 
Administration of steroids, with adequate blood sugar monitoring ,  
 
    minimises the risk of RDS. 
 
Tests for lung maturity includes  
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           L/S ratio,  
 
           Lamellar body count,     
 
           Phosphatidyl glycerol,  
 
           Surfactant -albumin ratio. 
 
 
Grenarche DG and Kjos et al proved that these studies have poor specificity 
 
Routine testing not required in exactly dated pregnancy 
 
 
 
 
 NEONATAL HYPOCALCEMIA AND HYPOMAGNESEMIA:    
 
Serum calcium levels <8mg/dl in term,    
 
    <7mg/dl in preterm 
 
Due to neonatal hypoparathyroidism 
 
Occurs few days after birth  
 
More incidence in preterm and asphyxiated babies 
 
Occurs in 7% of babies born to diabetic mothers 
 
Hypomagnesemia is due to increased renal losses in poor controlled  
 
    Diabetics 
 
 
 
 POLYCYTHEMIA:    
 
Venous hematocrit >65% 
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Tissue hypoxia is the basic pathology 
 
Increased viscosity of blood which in turn leads to vascular sludges, poor  
 
    circulation, microthrombi which poses risk of infarction to vital organs 
 
 
 LONG TERM COMPLICATIONS:     
 
Neurodevelopmental abnormalities like cognitive defects, autism 
 
Increased risk of metabolic syndrome and type 2 diabetes. 
 
 
  
20 
 
SCREENING AND DIAGNOSIS OF GDM : 
        
 
                        Early Diagnosis of GDM, is important to identify ‘fetus at risk  
 
of adverse outcomes’ and ‘women at risk of subsequent development of  
 
diabetes’. The occurrence of gestational diabetes mellitus may go unrecognised  
 
throughout the pregnancy unless complications arise. So in order to decrease the  
 
morbidity of  GDM in pregnancy, effective screening should be done for early  
 
recognition of the disease.(8) 
 
                            There remains a controversy regarding selective and universal  
 
screening  for GDM., based on some risk factors.  
 
                            ADA’s 4th international workshop on GDM in 1977  
 
recommends selective screening, based on criteria which divides low risk and  
 
high risk groups.(9) 
 
                             According to that criteria, the low risk groups were young  
 
Aged <25 yrs, with no family history or past history of GDM, with normal BMI  
 
and not a member of ethnic group of diabetes high risk. 
 
                              But this criteria cannot be applied to Indians, as India which  
 
is a part of south-asian ethnicity is more prone to develop diabetes.  
 
                            Indian women are a high risk ethnic group, which warrants  
 
‘universal screening’ because of high incidence of type 2DM in our community. 
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LIMITS OF SCREENING: 
 
-RBS, HBA1C, S.Fructosamine and samples timed according to meals are poor  
 
  tests for screening of GDM 
 
-Fasting glucose testing has high false positivity, to offer a good sensitivity at   
 
  the set cut off levels.(10) 
 
-Some women have normal FBS and PPBS, but response to glucose challenge  
 
  may be exaggerated. 
 
-Milder form of GDM will be missed, if glucose challenge is not done. 
 
 
 
ACOG (2011) suggests that universal screening by., 
 
 Patient history taking 
 
 Clinical risk factors assessment, 
 
  Random blood glucose test (at booking visit),  
 
 Oral Glucose challenge test (24-28 weeks of gestation)   
 
 GDM is diagnosed based on 100gm 3 hour OGTT (diagnosed as GDM if pt  
 
having two or more positive values). 
 
 
ACOG recommends TWO STEP APPROACH, (9) 
 
 
STEP-1 50gm Oral glucose challenge test (O Sullivan test) is performed, 
 
STEP-2If positive, then confirmed by OGTT.   
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GLUCOSE CHALLENGE TEST: 
 
                        Oral glucose of 50 gm is given, irrespective of  last meal and Venus  
 
blood glucose measured 1 hour later. 
              
                         Sensitivity depends on the cut off value set for the test. When 
 
130 mg/dl is set as the upper limit, the sensitivity  is 90 %. The same falls as 80 % if  
 
Cut-off limit is adjusted to 140 mg/dl. This will unnecessarily subject  a large number  
 
of population  to OGTT. 
 
                          To overcome the limitations, of  this O’ Sullivan’s test., American  
 
Diabetic Association (ADA) and The IADPSG (2011)  recommended  ‘one step 
 
diagnostic 75gm 2 hour OGTT’ (diagnosed as GDM, if any one of the three 
 
values is high) 
 
 
TEST CUT-OFF 
FBS >92mg/dl 
POST 1 HR >180mg/dl 
POST 2 HR >153mg/dl 
 
 
                               These cut offs are lower than the traditional values. This result was 
 
based on, the ‘ HAPO study’  (Hyperglycemia And Pregnancy Outcome study) 
 
which implies increased complications can occur, even below the traditional 
 
cut- offs that are set for diagnosis of GDM. 
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                                       The following is the algorithm that was suggested  by 
 
combining the recommendations of ADA and IADPSG in 2011 
 
 
Testing all women, at the first antenatal visit at < 13 weeeks ( to reduce  
 
     complications by early detection) 
 
Testing women who have any of the following risk factor  
 
 Non-Caucasian ethnicity 
 
 BMI>25 kg/m2 
 
 Past History of GDM or pre-diabetes, 
 
  Still birth(unexplained), 
 
 H/o anomalous baby. 
 
 Previous H/o big  baby 4000gm or more 
 
 Family H/o First-degree relative with DM 
 
 Glycosuria 
 
 H/o any Drug intake that raise glucose levels (steroids, betamimetics, 
 
          atypicalAntipsychotics) 
 
 H/o of Polycystic ovarian syndrome, 
 
 H/o Cardiovasculardisease, Hypertension, Hyperlipidemia. 
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Diagnosis of overt diabetes include any one of the following criteria: 
 
-Fasting glucose  >126mg/dl 
 
-Random glucose  >200mg/dl 
 
-HBA1C  >6.5% 
 
 
 
 
 
Diagnosis of GDM includes the following criteria: 
 
-HBA1C  <5.7 to 6.4 % 
 
-Fasting glucose   >92mg/dl  to  <126 mg/dl  
 
 
                        
                       
                  Seshiah et al has debated that, ADA & IADPSG suggestion has  
 
the following disadvantages… 
 
 
  
1. The ‘ HAPO study’ was essentially conducted in  Caucasian  population  
 
except in Bangkok and Hongkong. 
 
2. For any antenatal visit, women does not come in fasting state mostly 
 
3. The dropout rate is very high when adviced to do an OGTT in the next visit.,  
 
especially in developing countries ,where the of antenatal visits  are less  
 
numbered.   
 
4. Glycosylated Hb testing is not possible in low resource settings because of 
 
the cost and lack of technically qualified staff. 
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                                      In Developing countries like India, to overcome these  
 
problems , the Diabetics In Pregnancy Study group India (DIPSI), has recommended a  
 
single step diagnostic  procedure for all pregnant patients. In this test, the pregnant  
 
women,  during their antenatal visit, are given 75 gm of anhydrous glucose orally,  
 
irrespective  of the fasting status and timing of previous meal.  Post 2 hour blood  
 
glucose value is observed , and  if it is more than or equal to 140 mg/dl , they are  
 
diagnosed as GDM. It is approved by Ministry of Health, Government of India and  
 
WHO. 
 
 
 
Advantages of  DIPSI,  as approved  by Seshiah et al: 
 
 No need of fasting state.  
 
 Can be performed at the first visit itself. 
 
 It can be used both as screening as well as diagnostic procedure. 
 
 It can be repeated  in 2nd and 3rd trimester. 
 
 
ORAL GLUCOSE TOLERANCE TEST: 
 
 
 The test is done in the morning 
 
  Needs at least overnight fasting of eight to twelve hours. 
 
  The subject can take unrestricted diet, which contains at least 150g  
 
carbohydrate per day,  
 
 No limitation of  physical activity.  
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 Should not smoke throughout the test. 
 
The test done with oral anhydrous glucose of 100 gm taken once.  
 
Then blood is drawn at hourly interval.(12) 
 
 
Blood sugar 
 
Carpenter&coustan NDDG 
Fasting 
 
>95 >105 
Post 1hr 
 
>180 >190 
Post 2hr 
 
>155 >165 
Post 3hr 
 
>140 >145 
 
 
NDDG (national diabetes data group) (13) 
 
 
                                Diagnostic criteria from NDDG is used most often. When  
 
Compared  with the NDDG criteria, the carpenter and coustan criteria always led to  
 
an over-diagnosis of GDM in 54% of pregnant women , associated with an increased  
 
cost and no effective improvement in perinatal outcomes. 
 
 
The ADA cut off values, to diagnose GDM (With100 g of glucose): 
 
Fasting blood glucose level >95 mg/dl (5.33 mmol/L) 
 
 Post 1 hr blood glucose level>180mg/dl (10 mmol/L) 
 
 Post 2 hr blood glucose level>155mg/dl (8.6 mmol/L) 
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Post3 hr blood glucose level>140mg/dl  (7.8 mmol/L)  
 
 
                              In 1964, O’Sullivan and Mahan were the first to demonstrate that  
 
the blood  glucose values, can be used to diagnose GDM.  Four random whole blood  
 
samples were drawn. The positive result, was based on two values reaching  or , 
 
exceeding the cut off value. 
 
                            Based on further studies, few alterations in O’Sullivan’s criteria  
 
were adopted. In this, whole blood was changed to plasma sample, and changes were  
 
made in the in cut off for GDM. (14) 
 
                              In a retrospective study, conducted by  O’Sullivan and Mahan,  
 
 100 grams of glucose was used for oral glucose tolerance test. This was designed and 
 
 believed to diagnose the risk of developing type 2 diabetes mellitus in the future. 
 
 
URINARY GLUCOSE TESTING; 
 
                                  Due to increased GFR in pregnancy, physiological glycosuria  
 
occurs. This is responsible for 50 % of women having glycosuria in their urine on  
 
dipstick  tests at some time in their pregnancy. 
 
                                  Glycosuria has the sensitivity of 10 %  and  positive predictive  
 
value of 20 %, in first and second trimester, when used as a marker of GDM 
 
                         Glycosuria of   2+ or above, in 1 occasion (or)  1+ or above, in 2  
 
occasions or more detected by urine dip strip, during routine antenatal visit may  
 
indicate undiagnosed GDM. This is an indication for further testing to 
 
exclude GDM (NICE 2015) 
 
 
 
28 
 
MANAGEMENT OF GDM: 
 
 
 Adequate control of blood glucose, is necessary to prevent the maternal and fetal  
 
     morbidity which thereby, improves quality of life of mother and the fetus. 
 
     Crowther Et al (ACHOIS study 2005).(15) 
 
Daily self monitoring of  blood glucose, is very essential for women with 
 
    GDM. 
 
Ultrasound to detect macrosomia in pregnancy. 
 
Treatment  starts with life style modification and Medical Nutrition Therapy. 
 
Insulin therapy is initiated, if lifestyle modification and MNT fails. 
 
Maintenance of postprandial blood glucose under control is important 
 
Daily Fetal Movement Count to be monitored . 
 
Hypoglycemic events to be prevented. 
 
Bi-weekly NST and USG Doppler to be done for fetal well being. 
 
Regular Follow up of GDM women is necessary, since most of them develop 
 
    type 2 DM in future. Must be adviced to do repeat OGTT., two to four months after  
 
    delivery. 
 
Low dose hormonal contraceptive pills can be advised after delivery. 
 
 
                               In the 4th international conference, on GDM, recommendation  
 
were  put-forth to maintain the following blood sugar values. 
  
Preprandial glucose less than 95 mg/dl,  
  
1hr PPBS<140 mg/dl, and 
  
2hr PPBS < 120 mg/dl. 
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                             ACOG  also recommends the same, except that the 1-hour  
 
Postprandial glucose value is acceptable at either 130 or 140 mg/dl. 
 
 
                              Jovanovic Et al. proposed another strict guideline with   
 
FBS   < 90 mg/dl and PPBS< 120 mg/dl , to prevent complications of GDM. 
 
 
                          Agarwal Et al, in the year 2007 conducted a prospective study , which  
 
recruited 668 Patients for the study. This study population included 334 women with  
 
GDM and another 334 women without GDM., for whom they calculated the mean  
 
blood glucose level.(16) Women with GDM, who had a mean blood glucose level of  
 
87mg/dl, had increased rate of IUGR and women with mean blood glucose level of  
 
104mg/dl had increased rate of  LGA  infants, when compared with the control group.  
 
Based on this study it was understood  that  hyperglycemia must be controlled, but not  
 
to be over treated, because it is harmful to the fetus, by increasing the risk of IUGR. 
 
 
                                        Diabetes in Early Pregnancy Study conducted by Boyd Et al,  
 
emphasised that, the best predictor of percentile birth weight is PPBS levels measured  
 
in 3rd  trimester of pregnancy. Dose of insulin therapy is to be titrated according to  
 
PPBS, better than preprandial glucose levels.with this study, it was found that the 
 
incidence of neonatal hypoglycemia, macrosomia, and cesarean delivery for 
 
cephalopelvic disproportion found to be decreased. 
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MEDICAL NUTRITION THERAPY:  
 
 Aims to improve nutritional status of the mother and fetus.(17) 
 
 Helps to maintain adequate weight gain in the antenatal women. 
 
 Maintains normoglycemia and prevents  ketoacidosis. 
 
 In a normal pregnancy, 1st  trimester does not need increased energy 
 
            requirement. Whereas in 2nd  and 3rd  trimester an additional of 
 
           300kilocalories /day is required. 
 
 GDM women of normal weight, calorie intake of 30 kcal/kg/day is  
 
recommended. 
 
 GDM women with obesity(BMI>30 kg/m2), 33 % of the calorie restriction, of  
 
their estimated energy needs is recommended (~25 kcal/kg/day). This diet 
 
           restriction does not cause any ketonuria. More calorie restriction is needed in 
 
           morbidly obese women.  
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 Very cautious about ketosis, when advised more  calorie restriction. 
 
 GDM mother with ketonemia during pregnancy, are found to 
    
           have long term complications such as poor psychomotor 
 
           skills and low intelligence, in their children 
 
 
 It is ideal to measure pre-breakfast levels of ketone in patients, who 
     
           practice to take low calorie diet or carbohydrate restricted diet. 
 
 Intake of low glycemic index food is adviced. 
 
 Carbohydrates should be splitted, GDM Women are adviced to take three  
 
small- to medium-sized meals and three snacks per day., to limit the  
 
carbohydrate intake to 40% of total daily calorie requirement which decrease  
 
postprandial glucose.(18) 
 
 Restricting the carbohydrate at breakfast to 33% is needed, to meet the desired  
     
           postprandial glucose, as the Insulin resistance is high in the morning. 
 
 
EXERCISE:   
   
 
 NICE 2015   recommends 30 minutes of mild to moderate exercise daily. 
 
 Mottola MF conducted an RCT, it was a small trial in which they had taken  
 
who was two groups of people, one group were GDM women managed with 
 
           diet plus exercise, another group was managed with diet alone, for 6 weeks. 
    
          They found that diet-plus- exercise group had a significant decrease in 
 
          HBa1c levels and decrease of both fasting and post 1-hour glucose level during  
 
           OGCT,  compared to the diet group.(19) 
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INSULIN THERAPY:     
 
 Insulin therapy is the Gold standard therapy  in the management of GDM and 
 
           pregestational diabetes. (20) 
 
 Most common recommendation is., short acting Regular insulin(onset of action  
 
30 minutes lasting for 6-8 hours) and intermediate acting NPH  insulin (onset  
 
of action 1-hour,lasting for 10-14hours). 
 
 Insulin therapy is initiated when MNT fails, to maintain blood glucose 
   
            level at desired ranges. 
 
 In a study by kierck et al, GDM women treated with insulin. showed a  
 
decreased incidence of macrosomia. 
 
 A large prospective study, which was conducted in almost 2500 women with 
 
           GDM,was compared the effect of intensive versus conventional management of 
 
           GDM. Women were randomized, accordingly to the intensive management  
 
           group and conventional management group. It has been clearly concluded from  
 
           this study that the intensively  managed group showed decreased rate of  
 
           macrosomia,  neonatal intensive care admission, respritory  complication.  
 
 No study is proved to demonstrate optimal insulin regimen till date 
 
  The type and dose of insulin must be tailored to meet each patient’s  
 
 requirements individually. 
 
 Human insulin, is currently recommended by ADA. Recent research has 
 
           added newer rapid acting insulin lispro and aspart whose action begins 
 
           within 15 minutes. 
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 Insulin lispro, is considered to be safe in pregnancy which belongs to cat B by  
 
FDA. 
 
 Insulin aspart, is considered as pregnancy category C by the FDA. 
 
           Insulin aspart, is found to be effective in decreasing postprandial glucose 
 
           concentration.  
 
 Only one case report is available regarding., the use of insulin glargine in 
 
          pregnancy. It is pregnancy category C( by FDA). 
 
 
 
 
ORAL HYPOGLYCEMIC AGENTS (OHA): 
 
                             Two OHA have been recognised for its use in pregnancy. They are  
 
Metformin (Biguanide group) and Glyburide. ADA also recommends the use of these  
 
drugs. In the past, there was much concern regarding the teratogenecity,  of these  
 
drugs due to their  transplacental  transfer.(21) 
 
                             Metformin can be used in pregnant women with GDM especially  
 
with history of PCOS  and  obesity. It  is considered to be pregnancy category B drug  
 
by FDA. According to a study by Jamie et al,  Metformin is an effective and safe  
 
alternative to insulin,  in patient with GDM. There found to be no significant  
 
difference in birth weight between the Metformin and insulin group. 
 
In an another study, which is a retrospective cohort study, it was been found that the  
 
women treated  with Metformin, had an reasonable increased prevalence of  
 
preeclampsia and perinatal  mortality, although further still more larger studies are  
 
needed, for evaluating the safety of the drug called Metformin during pregnancy. 
 
                                   Pratap et al , who conducted a prospective study involving  
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women with PCOS and also women with type-two DM who used Metformin in  
 
pregnancy.  They had found to have no unpleasant pregnancy outcome.(22) 
 
                                 
                                            The second generation sulfonylurea’s like Glyburide can cross 
 
the human placenta insignificantly in experimental model., according to studies. 
 
ADA( 2016),  ACOG has not recommended this drug ,since then we need larger 
 
studies to support the further use of this drug. 
 
 
 
SERUM FERRITIN: 
 
                       
                       Serum ferritin, which is a iron storage protein, is an universal  
 
intracellular protein. It releases iron, in a controlled manner. It is been produced  
 
invariably by almost all living organisms, like algae, bacteria., plants and all  
 
animals and humans.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       In humans, its special characteristic is the buffering action,  
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between iron overload and iron deficiency. It is found as a cytosolic protein. It  
 
is secreted into the serum in minimal quantities. In the serum, it acts as iron  
 
carrier. It is a marker of , iron status of the body. So it is used as a diagnostic  
 
test in anemia. 
 
                        Ferritin, is a globular protein of 450kDa with complex  
 
structure, containing , 24 protein sub units, they altogether form a nanocage. It  
 
has multiple metal protein interactions. Iron is stored as a soluble and a nontoxic  
 
form, by this interaction. Ferritin without iron, is called as apoferritin.     
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         Mitochondrial ferritin, which was recently identified as protein  
 
precursor, is now classified as, metal binding protein, located in the  
 
mitochondria. It is there processed into., mature protein, to form ferritin shells.  
 
It is 67% helical. It was been studied in detail by ramachandran plot. 
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FUNCTIONS OF SERUM FERRITIN: 
 
 Iron storage 
 
 Ferroxidase activity 
 
 Immune response 
 
 Stress response 
 
 Component of yolk 
 
 Cellular molecular functions 
 
 
 
S.FERRITIN AS IRON STORAGE PROTEIN: 
 
              
                          Ferritin stores iron in a non toxic form., to deposit and  
 
transfer as a safe form wherever and whenever required. In different cells, it  
 
exhibits different actions. This action is under control of mRNA (messenger  
 
RNA). This manages its action and storage in various aspects. Ferritin  
 
production is triggered by the presence of iron.(23) 
 
  
                              Free iron is always toxic to the cells. It acts like catalyst. It  
 
forms free radicals which are reactive oxygen species. This is by Fenton  
 
reaction. To protect from the stress of free radical induced injury to the cells,  
 
binding to iron in various tissue compartments are done. 
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                               In the cells, iron is stored in the form of protein complex like  
 
ferritin and hemosiderin. Free ferrous iron bind to apoferritin, and further stores  
 
in the form of ferric state. Protein aggregates are formed, as hemosiderin when  
 
ferritin is accumulated in the reticulo-endothelial system. Hemosiderin is less  
 
readily available for use. But the ferritin part is always readily available for use  
 
by the RES., which is degraded in the lysosomes. 
 
                                  
                              Serum ferritin levels correlates., with the level of total iron body  
 
stores. This makes serum ferritin, FR5R1, as the most convenient laboratory test, to  
 
estimate the level of iron in the body. 
 
                                The no. of iron atoms., is on an average 1000-1500  normally in a  
 
ferritin molecule, to the maximum of 4500 iron atms 
 
 
 FERROXIDASE ACTIVITY OF FERRITIN: 
 
                        Ferritin  has subunits- L “light”  , H “heavy”,  M “middle”  
 
subunits.,   based on molecular weight. H subunits have ferroxidase activity., in  
 
which ferrous iron(Fe2+) is converted to ferric iron (Fe3+) form. So now the  
 
deleterious reaction, between ferrous iron, and the hydrogen peroxide which  
 
forms free radicals (hydroxyl radical) is limited. This is the fenton reaction. This  
 
activity occurs at the middle of the H subunit, at a diiron binding site. After  
 
oxidation, the product is in the the ferroxidase center. Liganding prevents  
 
reactivity of iron.  
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                          Degradation of ferritin into hemosiderin and lipo ferritin occurs.  
 
Hemosiderin levels are elevated in iron overload state. It can be used as  
 
prognostic marker in disease state. 
 
 
                          The light chain subunit, has no ferroxidase activity. But the  
 
light  chain subunit, has electron transfer action across the protein cage. 
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FERRITIN AND IMMUNE AND STRESS RESPONSE: 
 
                   Ferritin levels, drastically increase in the presence of infections  
 
and inflammations and cancer. In infections, the release of endotoxins is an up- 
 
regulator, for the gene coding the ferritin, which is found to increase the levels  
 
of ferritin in infections. The exception to this, is the pseudomonas infection, in  
 
which the serum levels found to be decreased in first 48 hours of infection. 
 
Thus, the iron stores of the infected body, are denied to the infective agent,  
 
impending its metabolism.(24) 
 
 
             
 
               Ferritin levels are found to get increased , in response to stress such  
 
as anoxia., which implies that ferritin is also an acute phase reactant. This shows  
 
that serumferritin is an important inflammatory marker.(25) 
 
 
40 
 
 
 
The following are few inflammatory conditions, where serum ferritin levels are  
 
markedly increased., which excludes infections. 
 
 Acute ARDS 
 
 Atherosclerosis 
 
 Malignancy 
 
 Liver cirrhosis 
 
 Type 2 DM 
 
 Metabolic syndrome 
 
 NAFLD 
 
 Preeclampsia 
 
 Rheumatoid arthritis 
 
 SLE 
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SERUM FERRITIN AND INSULIN RESISTENCE:  
 
                        Elevated serum ferritin is associated with central obesity,  
 
which inturn  is associated with elevated blood glucose, elevates blood pressure  
 
especially the diastolic BP. Thereby decreasing the storage form of iron is one  
 
of the modality of treatment for managing resistant hypertension. 
 
 
                             Islet cells of pancreas are particularly sensitive to injury., due  
 
to free oxygen radicals., thereby has high concentration of ferritin to withstand  
 
the stress as ferritin exhibit antioxidant property(26) 
 
 
 
 
 
                           Mutation in H6-3D, C2824 gene is more frequently seen in  
 
type 2 diabetes. This gene is involved in hemochromatosis along with C2824  
 
leading to heterozygosity. Frequent blood donation thus offers protection  
 
against diabetes. 
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                            Iron overload in liver with increased ferritin without elevated  
 
transferring saturation , is identified as a new marker of hemochromatosis which  
 
is seen associated with resistance to insulin. This new syndrome is known as  
 
IR-HIO. (insulin resistance associated hepatic iron overload). Insulin resistance  
 
is frequently seen in chronic HCV infection too. 
 
 
 
 
                    Insulin causes redistribution of transferring receptors to cell  
 
surface, which in turn causes co-localisation of insulin dependent GLUT and 
 
IGF II receptor in adipocytes. Increased iron, inhibits insulin action in the liver,  
 
there by causing hyperinsulinemia. This hyperinsulinemia glycates transferrin  
 
receptors , and causes increases free iron, thus overall increasing the ferritin  
 
synthesis. Hyperinsulinemia adds to this action by causing increased iron by  
 
oxidative stress. (27) 
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                       Glycated transferrin  in diabetic state is unable to bind iron ,  
 
leading to elevated free iron to be stored as ferritin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SYMPTOMS OF HIGH FERRITIN: 
 
 Fatigue 
 
 Joint pain 
 
 Palpitations 
 
 Abdominal pain. 
 
SYMPTOMS OF LOW FERRITIN: 
 
 Giddiness 
 
 Headache 
 
 Leg cramps 
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 Breathlessness 
 
 Tinnitus  
 
 
TEST PRINCIPLE OF SERUM FERRITIN: 
 
 S.Ferritin is available in two forms: 
 
1)  H- heart and kidney. 
 
2) Liver and spleen. 
 
Serum ferritin is more sensitive than measuring serum iron 
 
QUANTIMUNE FERRITIN IRMA KIT:  
 
-latest test to measure ferritin 
 
-high cost 
 
-less time to test 
 
-traces  Iodine-125 labelled antibody to ferritin which are coated on polyacryl 
 
beads. Then the levels are measured by gamma counter, which is equal to the  
 
ferritin levels., measured by RIA. 
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                                GDM is a state of insulin resistance than decreased insulin  
 
secretion. This insulin resistance can also co exists with obesity and PCOS and  
 
pre-existing type 2 diabetes.  
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                                    As serum ferritin levels are increased in the states  
 
of  hyperinsulinemia and insulin resistance, GDM which is associated with  
 
insulin resistance, should have the possibility of elevated serum ferritin levels.  
 
This serum ferritin levels, tends to increase before the symptoms of insulin  
 
resistance and development of GDM manifests. So measuring serum ferritin  
 
levels early in the pregnancy just before the period of developing GDM, could  
 
guide us to a better awareness about the possibility of developing GDM. (28) 
 
Thereby reducing the morbidity of GDM. 
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                     AIMS AND OBJECTIVES 
 
AIM OF THE STUDY: 
 
To determine the association between moderately elevated Serum Ferritin levels  
in mid-pregnancy  and risk of Gestational Diabetes Mellitus .  
 
OBJECTIVE OF THE STUDY: 
To investigate the effect of a higher level of maternal serum Ferritin and  
 
thereafter describe a generic framework for combining this screening  
 
information with designing a prophylactic intervention in the future. 
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               MATERIALS AND METHODS 
 
 
STUDY CENTRE   :  Department of Obstetrics and Gynecology , 
                                     Madras Medical college, 
                                     Chennnai 
 
DURATION OF      :  One year 
        STUDY 
STUDY DESIGN    : Prospective  study 
 
SAMPLE SIZE        :  100  
 
INCLUSION CRITERIA: 
      
 Pregnant women in gestational age 16 to 24 weeks as calculated by LMP  
 
and dating scan  
 
EXCLUSION CRITERIA: 
 
Pregnant women with  
 
 Anemia  (Hb<11gm/dl), 
 
  Pre-eclampsia, 
 
 Type 1 and type 2 diabetes 
 
 Hematological disorders ( sickle cell anemia, hemoglobinopathy,  
 
thalassemia) 
 
 Auto immune disorders( SLE, rheumatoid arthritis) 
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 Hepatitis, Any fever 
 
 Any local and systemic infection 
 
 
 
                          100  women attending the antenatal clinic in 16-24 weeks of  
 
gestation (as selected by  inclusion  criteria and exclusion criteria )were enrolled  
 
in the study. Data was collected from the study participants after explaining  
 
about the study to them and getting their informed consent. To avoid selection  
 
bias, the participants   were chosen based on a randomised approach. The  
 
questionnaire for data collection was filled by the principal investigator by  
 
interviewing the participant in person. The participants were interviewed in  
 
person, during their routine antenatal visit to ensure their comfort and to have  
 
their fullest cooperation. 
 
                                
                             Venous blood samples were obtained from the patient  
 
between16 to 24 weeks' gestation to measure serum ferritin level by fully  
 
automated bidirectionally interfaced chemi-luminescent immuno-assay. serum  
 
Ferritin levels  measured are grouped in quintiles.  
 
 
                   The reference value for serum Ferritin in pregnancy is 12-150ng/ml.   
 
The serum ferritin  observed in 100 study population are grouped in quintiles  
 
and number of GDM mothers diagnosed in each quintile is studied 
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SCREENING FOR GDM 
 
 All patients will undergo  OGCT (75gms of glucose) between 24- 
 
28 weeks. And again at 32-34 weeks 
 
 If the value is > 200 mg/dl  patient is considered to have GDM 
    
                                                              OR 
 If plasma glucose level > 140 mg/dl  patient at increased risk of 
 
developing GDM   will then undergo  OGTT 
 
 
OGTT: 
 
FBS level oral intake of 100 gms glucose  measuring blood 
 
glucose level at 1,2 and 3 hrs. 
 
 
Patients are considered to have GDM if 2 or more values of the 4 
 
exceed described in carpenter &Coustan Criteria (American diabetes 
 
association 2009 ) 
 
           BLOOD GLUCOSE 
 
       Carpenter & coustan cut-off 
FBS 
 
>95mg/dl 
POST 1 HR 
 
>180mg/dl 
POST 2 HR 
 
>155mg/dl 
POST 3 HR 
 
>140mg/dl 
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        OBSERVATION AND ANALYSIS 
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AGE DISTRIBUTION OF STUDY GROUP:  
 
 
               The major study population belonged to 25-28 years. 
 
AGE DISTRIBUTION OF GDM: 
 GDM Total 
No Yes 
AGE GROUP  
21-24 Years 
Count 21 6 27 
% within GDM 33.3% 16.2% 27.0% 
25-28 Years 
Count 19 14 33 
% within GDM 30.2% 37.8% 33.0% 
29-32 Years 
Count 20 10 30 
% within GDM 31.7% 27.0% 30.0% 
33-36 Years 
Count 3 7 10 
% within GDM 4.8% 18.9% 10.0% 
TOTAL 
Count 63 37 100 
% within GDM 63% 37% 100% 
 
  
27%
33%
30%
10%
Age group
21-24 Years
25-28 Years
29-32 Years
33-36 Years
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AGE DISTRIBUTION OF SERUM FERRITIN: 
 S_FERRITIN_GROUP TOTAL 
<30 30-60 60-90 Above 90 
AGE_ 
GROUP 
21-24 Years 
Count 16 6 4 1 27 
% within 
S_FERRITIN_GROUP 
33.3% 25.0% 18.2% 16.7% 27.0% 
25-28 Years 
Count 15 7 10 1 33 
% within 
S_FERRITIN_GROUP 
31.2% 29.2% 45.5% 16.7% 33.0% 
29-32 Years 
Count 15 9 5 1 30 
% within 
S_FERRITIN_GROUP 
31.2% 37.5% 22.7% 16.7% 30.0% 
33-36 Years 
Count 2 2 3 3 10 
% within 
S_FERRITIN_GROUP 
4.2% 8.3% 13.6% 50.0% 10.0% 
TOTAL 
Count 48 24 22 6 100 
% within 
S_FERRITIN_GROUP 
48% 24% 22% 6% 100.0% 
 
 
ASSOCIATION OF AGE GROUP & S.FERRITIN LEVELS: 
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DISTRIBUTION OF BMI IN THE STUDY GROUP: 
  
 
 
ASSOCIATION OF BMI AND GDM: 
 GDM TOTAL 
No Yes 
BMI_GROUP 
<18.5 
Count 1 0 1 
% within GDM 1.6% 0.0% 1.0% 
18.5-24.99 
Count 61 26 87 
% within GDM 96.8% 70.3% 87.0% 
25-30 
Count 1 11 12 
% within GDM 1.6% 29.7% 12.0% 
TOTAL 
Count 63 37 100 
% within GDM 63% 37% 100.0% 
Pearson Chi-Square=17.861** p<0.001 
 
 
 
1%
87%
12%
BMI GROUP
<18.5
18.5-24.99
25-30
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BMI AND S.FERRITIN: 
 S.FERRITIN GROUP TOTAL 
<30 30-60 60-90 Above 90 
BMI 
GROUP 
<18.5 
Count 0 1 0 0 1 
% within 
 S.FERRITIN GROUP 
0.0% 4.2% 0.0% 0.0% 1.0% 
18.5-24.99 
Count 47 22 15 3 87 
% within  
S.FERRITIN GROUP 
97.9% 91.7% 68.2% 50.0% 87.0% 
25-30 
Count 1 1 7 3 12 
% within  
S.FERRITIN GROUP 
2.1% 4.2% 31.8% 50.0% 12.0% 
TOTAL 
Count 48 24 22 6 100 
% within  
S.FERRITIN_GROUP 
48% 24% 22% 50% 100.0% 
Pearson Chi-Square=25.305** p<0.001 
 
                                     The serum ferritin levels were found to be increased in  
 
BMI group of 25-30.  The observed p-value is <0.001 and is found to be  
 
significant. This indicates insulin resistance in obesity is associated with  
 
increased serum ferritin levels and also association of GDM. 
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ASSOCIATION OF BMI AND S.FERRITIN: 
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OBSTETRIC CODE OF STUDY GROUP: 
 
 
 
 
OBSTETRIC CODE AND GDM: 
 
 
GDM Total 
No Yes 
OBS .CODE 
Primi 
Count 40 21 61 
% within GDM 63.5% 56.8% 61.0% 
Multi 
Count 23 16 39 
% within GDM 36.5% 43.2% 39.0% 
TOTAL 
Count 63 37 100 
% within GDM 63% 37%% 100.0% 
 
 
 
 
 
61%
39%
OBS Code
Primi
Multi
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OBSTETRIC CODE AND S.FERRITIN: 
 
 S.FERRITIN GROUP TOTAL 
<30 30-60 60-90 Above 90 
OBS#CODE group 
Primi 
Count 28 16 15 2 61 
% within  
S.FERRITIN GROUP 
58.3% 66.7% 68.2% 33.3% 61.0% 
Multi 
Count 20 8 7 4 39 
% within  
S.FERRITIN GROUP 
41.7% 33.3% 31.8% 66.7% 39.0% 
TOTAL 
Count 48 24 22 6 100 
% within 
 S.FERRITIN GROUP 
48% 24% 22% 6% 100.0% 
 
 
 
ASSOCIATION OF S.FERRITIN AND PARITY: 
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RISK FACTOR IN THE STUDY POPULATION:  
 
 
 
   The risk factors observed in the study population were… 
-PCOS 
-Family history of GDM 
-Prev GDM 
-BOH 
-Prev Big baby 
-Prev IUFD 
 
 
72%
1%
9%
11%
4%
2%
1%
28%
RISK FACTOR
No Risk Factors
BOH
F/H- DM+
PCOS
prev big baby
Prev GDM
PREV IUFD
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RISK FACTORS AND SERUM FERRITIN: 
 
 S.FERRITIN GROUP TOTAL 
<30 30-60 60-90 Above 90 
RISK  
 
FACT
OR 
BOH 
Count 0 0 0 1 1 
% within 
 S.FERRITIN GROUP 
0.0% 0.0% 0.0% 20.0% 3.6% 
F/HDM+ 
Count 1 3 3 2 9 
% within 
 S.FERRITIN GROUP 
20.0% 50.0% 25.0% 40.0% 32.1% 
PCOS 
Count 2 3 6 0 11 
% within 
 S.FERRITIN GROUP 
40.0% 50.0% 50.0% 0.0% 39.3% 
PREV BIG BABY 
Count 1 0 2 1 4 
% within 
 S.FERRITIN GROUP 
20.0% 0.0% 16.7% 20.0% 14.3% 
PREV GDM 
Count 1 0 1 0 2 
% within 
 S.FERRITIN GROUP 
20.0% 0.0% 8.3% 0.0% 7.1% 
PRE IUD 
Count 0 0 0 1 1 
% within 
 S.FERRITIN GROUP 
0.0% 0.0% 0.0% 20.0% 3.6% 
TOTAL 
Count 5 6 12 5 28 
% within  
S.FERRITIN GROUP 
100.0% 100.0% 100.0% 100.0% 100.0% 
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                                 In the study, The risk factors like family history of DM,  
prev GDM, BOH, prev IUFD, PCOS were significantly associated with  
increased serum ferritin levels. 
 
INDEPENDENT SAMPLES TEST 
 N Mean 
Std. 
Deviation 
Std. Error 
Mean t value p value 
S#FERRITIN RISK 
FACTORS 
28 57.8157 27.52998 5.20268 5.492** p<0.0001 
NO RISK 
FACTORS 
72 32.0715 17.97718 2.11863 
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                     The p-value of risk factors association with raised derum ferritin  
levels was found to be <0.001 and is significant. 
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Hb% OF STUDY GROUP: 
 
 
 
 
Hb%  AND GDM: 
 GDM TOTAL 
No Yes 
HB% 
11-12 
Count 41 6 47 
% within GDM 65.1% 16.2% 47.0% 
12.1-14 
Count 22 31 53 
% within GDM 34.9% 83.8% 53.0% 
TOTAL 
Count 63 37 100 
% within GDM 63% 37% 100.0% 
Pearson Chi-Square=22.342** p<0.001 
 
 
 
47%
53%
Hb% 
11 to 12
12.1 to 14
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HB% AND S.FERRITIN: 
 S.FERRITIN GROUP TOTAL 
<30 30-60 60-90 Above 90 
HB% 
11-12 
Count 33 11 3 0 47 
% within 
 S.FERRITIN GROUP 
68.8% 45.8% 13.6% 0.0% 47.0% 
12.1-14 
Count 15 13 19 6 53 
% within  
S.FERRITIN GROUP 
31.2% 54.2% 86.4% 100.0% 53.0% 
TOTAL 
Count 48 24 22 6 100 
% within  
S.FERRITIN GROUP 
48% 24% 22% 6% 100.0% 
Pearson Chi-Square=24.280** p<0.001 
 
 
Hb% AND SERUM FERRITIN: 
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S.FERRITIN LEVELS OF THE STUDY GROUP: 
 
 
 
GDM IN STUDY GROUP: 
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S.FERRITIN AND GDM: 
 GDM TOTAL 
No Yes 
S.FERRITIN GROUP 
<30 
Count 44 4 48 
% within GDM 69.8% 10.8% 48.0% 
30-60 
Count 15 9 24 
% within GDM 23.8% 24.3% 24.0% 
60-90 
Count 4 18 22 
% within GDM 6.3% 48.6% 22.0% 
Above 90 
Count 0 6 6 
% within GDM 0.0% 16.2% 6.0% 
TOTAL 
Count 63 37 100 
% within GDM 63% 37% 100.0% 
Pearson Chi-Square=46.099** p<0.001 
 
 
                            There was significant association between GDM and ferritin  
levels in this study group 
 
 
 OUTCOME TOTAL 
GDM-INSULIN GDM-MNT 
S.FERRITIN 
GROUP 
<30 
Count 2 2 4 
% within OUTCOME 9.1% 13.3% 10.8% 
30-60 
Count 1 8 9 
% within OUTCOME 4.5% 53.3% 24.3% 
60-90 
Count 14 4 18 
% within OUTCOME 63.6% 26.7% 48.6% 
Above 90 
Count 5 1 6 
% within OUTCOME 22.7% 6.7% 16.2% 
TOTAL Count 22 15 37 
Pearson Chi-Square=12.801** p<0.001 
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 S.FERRITIN GROUP TOTAL 
<30 30-60 60-90 Above 90 
OUTCOME 
Insulin 
Count 2 1 14 5 22 
% within  
S.FERRITIN GROUP 
50.0% 11.1% 77.8% 83.3% 59.5% 
MNT 
Count 2 8 4 1 15 
% within  
S.FERRITIN GROUP 
50.0% 88.9% 22.2% 16.7% 40.5% 
TOTAL Count 4 9 18 6 37 
Pearson Chi-Square=12.801** p=0.005 
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independent samples test 
              GDM n mean 
std. 
deviation 
std. error 
mean  t value p value 
AGE no 63 26.810 3.496 0.440 2.141* 0.035 
yes 37 28.378 3.608 0.593 
BMI no 63 22.105 1.614 0.203 5.524* p<0.001 
yes 37 24.062 1.866 0.307 
HB no 63 11.884 0.574 0.072 6.097* p<0.001 
yes 37 12.638 0.635 0.104 
S.FERRITIN no 63 27.187 12.927 1.629 8.75 p<0.001 
yes 37 59.870 24.444 4.019 
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  N Mean 
Std. 
Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Minimum Maximum 
    
Lower 
Bound 
Upper 
Bound f value p value 
AGE <30 48 26.79 3.59 0.52 25.75 27.83 21.00 34.00 2.086 0.107 
30-60 24 27.46 3.36 0.69 26.04 28.88 22.00 35.00 
60-90 22 27.77 3.34 0.71 26.29 29.25 21.00 35.00 
Above 
90 
6 30.50 4.59 1.88 25.68 35.32 24.00 36.00 
Total 100 27.39 3.60 0.36 26.68 28.10 21.00 36.00 
BMI <30 48 22.32 1.53 0.22 21.88 22.76 19.70 26.10 13.626* p<0.001 
30-60 24 21.96 1.83 0.37 21.19 22.73 18.40 25.10 
60-90 22 24.16 1.49 0.32 23.50 24.82 21.50 26.40 
Above 
90 
6 25.50 2.46 1.01 22.91 28.09 22.70 29.10 
Total 100 22.83 1.95 0.19 22.44 23.22 18.40 29.10 
Hb <30 48 11.79 0.52 0.07 11.64 11.94 11.00 13.10 32.638* p<0.001 
30-60 24 12.22 0.54 0.11 11.99 12.45 11.20 13.10 
60-90 22 12.49 0.45 0.10 12.29 12.69 11.00 12.90 
Above 
90 
6 13.75 0.21 0.08 13.53 13.97 13.40 13.90 
Total 100 12.16 0.70 0.07 12.02 12.30 11.00 13.90 
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                        DISCUSSION 
 
                       This study was conducted in Department  of Obstetrics and  
 
Gynaecology, Madras Medical College ,Chennai.  The total of 100 patients have been  
 
analysed. The association of elevated serum ferritn levels in mid-pregnancy and  
 
the risk of gestational diabetes mellitus was studied as prospective study. 
 
                       
                      Similar studies have been done in the past. 
 
- The Camden study , by Xinhua et al in 2006., with 172 cases 
 
- Soubasi and pettridou et al in 2009., with 63 cases 
 
- Nilufar islam et al in 2008., with 100 cases 
 
- Prasad et al in 2010., with 100 cases. 
 
     
                        All these studies have been conducted to find the association  
 
between serum ferritin levels and GDM in non-indian population., except the  
 
study by Prasad et al, which has been conducted in Andhra Pradesh.   
 
            This is the first prospective study conducted in Tamil nadu, 
 
tertiary care institute like IOG, egmore, to find the association of serum ferritin  
 
with GDM. This study included 100 women attending, the antenatal clinic  
 
randomly with categorising under inclusion and exclusion criteria. Their  
 
haemoglobin levels at their vist from 16-24 weeks was analysed and those with  
 
above 11 gms were chosen for the study after obtaining valuable consent. The  
 
serum ferritin levels measured and grouped into four  and then they were  
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prospectively observed during their consecutive antenatal visits with OGCT   
 
and OGTT if needed. And also FBS, PPBS was monitored for women with term  
 
gestation. 
 
                      In this study, the main outcome studied was the association of  
 
serum ferritin with GDM. The reference range of serum ferritin in pregnant  
 
women was 12- 150 ng/ml. In this study, of 100 pregnant women, 48 had serum  
 
ferritin values <30ng/dl, 24 had 30-60 ng/ml., 22 had 60 -90 ng/ml and only 6  
 
women had serum ferritin above 90 ng/ml. This also implies that majority of the  
 
population studied randomly had low serum ferritin levels, reflecting their low  
 
iron stores and prevalence of iron deficiency , inspite of good haemoglobin  
 
levels. 
 
 
                            Among th 100 pregnant women in this study, only 37 had  
 
GDM diagnosed at some point of time in the current pregnancy. In that 37  
 
women, 22 were started on insulin and 15 were on medical nutrition therapy 
 
out of 37  who developed GDM, about 18 had ferritin values between  
 
60-90 ng/ml, and 6 had values above 90 ng/ml. and in this 6 women women  
 
with serum ferritin >90, 5 were started on insulin. This implies that high serum  
 
ferritin levels has required the need of insulin for their blood sugar control.  
 
Among 18 who had serum ferritin level 60-90ng/ml, majority ( about 14) had  
 
the need of insulin and remaining 4 just needed MNT for their adequate blood  
 
sugar control. The p-value of this association is <0.001. 
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                                There was significant association between increased BMI  
 
and high ferritin levels, who invariably developed GDM. 10 out of 12 women  
 
with high BMI had increased serum ferritin levels.This shows a clear  
 
correlation between obesity and insulin resistance and serum ferritin levels on  
 
higher range ,with risk of developing GDM. 
 
                              The risk factors associated with GDM were also observed in  
 
this study, and was found that, PCOS  and family history of GDM was mainly  
 
associated with increased ferritin levels and subsequently developed GDM.  
 
Hyperinsulinemia and insulin resistance association with serum ferritin levels  
 
has been highlightened by this observation. 
 
                            Possible mechanisms involving elevated serum ferritin levels  
 
and risk of GDM  were excess iron stores hypothesis and inflammation  
 
hypothesis. 
 
 
 
EXCESS IRON STORES HYPOTHESIS: 
 
                                       In non-pregnant status, higher iron stores are at risk of  
 
developing type 2 DM, which has been studied with extensive data. In pregnant  
 
women., Lao et al., observed that increased haemoglobin levels had an  
 
independent risk of developing GDM.  
 
                                       In our study, the study population, majority had low  
 
ranges of serum ferritin levels, indicating deficient iron stores.  
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INFLAMMATION HYPOTHESIS: 
 
                                  In experimental models, the inflammatory cytokines like  
 
TNF-1A and interleukin-1A, have been found to induce synthesis of ferritin.  
 
This shows that, in the presence of infection or inflammation, serum ferritin is  
 
not a reliable indicator of iron stores. Pregnancy is a kind of inflammatory state,  
 
which can be proved with raised CRP levels from early gestation. 
 
                                   Adipose tissue, seems to be a valuable determinant , with  
 
a chronic inflammation at a lower level constantly, indicated by raised CRP  
 
levels and increased fat mass in both pregnant and non pregnant people.  
 
Retnakaran et al observed raised CRP levels and GDM association , mediated  
 
with BMI.  
 
                                  Jiang et al, analysed CRP and ferritin are independent risk  
 
factors, for GDM. 
 
                                In our study, serum ferritin levels at a higher range was  
 
significantly associated with development of GDM with statistically significant  
 
p-value of <0.001. These data, suggests that, there may be systemic  
 
inflammation mediated by body mass and genetic susceptibility for developing  
 
GDM. 
 
 
 
 
 
78 
 
LIMITATIONS OF THE STUDY: 
                           
 Study population was small 
 
 Serum Ferritin tests  are costlier and not readily available. 
 
 Iron stores status of  study population. 
 
 Fetal outcome not  been  studied. 
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                             SUMMARY 
 
                         This prospective study, with 100 population of   
 
randomly selected pregnant women, attending the tertiary care centre for  
 
antenatal check up, was studied for elevated serum ferritin levels and the  
 
subsequent risk of developing GDM. 
 
                   
                                  The study population showed significant correlation of  
 
BMI and elevated ferritin range, with subsequent development of GDM. This  
 
showed that there is a positive association between body fat mass and chronic  
 
low grade inflammation in the body. This triggers increased s.ferritin synthesis,  
 
thus making s.ferritin a good marker of inflammation. So it is clear that obesity  
 
plays important role in the development of diabetes., with marker of raised  
 
ferritin. 
 
                                    
                                   There seemed to be positive correlation between presence  
 
of history of PCOS and risk of GDM, with elevated ferritin range. This seems to  
 
prove that insulin resistance and hyperinsulinemia of PCOS favours the  
 
development of GDM. Serum ferritin levels too, increases in hyperinsulinemia.  
 
Other risk factors associated were, BOH, prev GDM, family history of GDM,  
 
all showed a positive association with increased ferritin levels. 
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                             CONCLUSION 
 
                                    
                                    Diabetes mellitus is a common disorder in India. It is not  
 
uncommon to encounter GDM in pregnant women of Indian population. GDM  
 
is associated with, increased perinatal mortality and morbidity, if not controlled  
 
properly. Preconception councelling, early diagnosis at prompt stage, good  
 
glycemic control, monitoring of fetal well being ., all plays a significant role in  
 
improving the perinatal outcome. 
 
                                    
                                   It is essential to offer universal screening for pregnant  
 
women in India, as Indians are at risk of developing diabetes due to ethnicity. 
 
 
Early diagnosis is the first and foremost determinant of the outcome of the  
 
pregnancy. 
 
                                   
                                     Glycemic control must be optimum., and achieved by  
 
daily self monitoring, adequate diet control and exercise, and by use if insulin  
 
and OHA’s. Antepartum fetal well being monitoring is essential. It is  
 
done by ultrasound and biophysical profile monitor.  Intrapartum fetal  
 
monitoring is very essential for good perinatal outcome. 
 
                                     
                                       Early diagnosis by serum markers , which are easy to  
 
predict the risk of developing GDM, should be widely used for easy diagnosis.  
 
Serum ferritin in this study had a significant correlation with development of  
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GDM. High ferritin range is at risk of GDM. Routine use of monitoring of  
 
serum ferritin levels, during the antenatal visit in the mid trimester should be  
 
carried out, for early prediction of developing GDM. 
 
                            
                               Serum ferritin levels , apart from iron store action, is a good  
 
predictor of developing GDM. Elevated serum ferritin concentrations, at early  
 
gestational weeks, is associated with increased risk of developing GDM. This  
 
association is mediated by fat mass of the mother and obesity , at least in part.  
 
This data in this study suggests a possible link., between high serum ferritin and  
 
low grade inflammation and insulin resistance in pregnancy., which creates the  
 
risk of developing GDM. 
 
                           
                              Though significant association was analysed in this study,  
 
between serum ferritin in higher levels and risk of developing GDM, still larger  
 
studies are required to prove this association in a significant large population.  
 
Study on fetal outcome to be emphasised in further studies. 
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KEYWORDS 
 
 ACOG       American College Of Obstetrics and Gynecology 
 
 WHO         World Health Organisation 
 
 ADA          American Diabetes Association 
 
 HAPO        Hyperglycemia and Adverse Pregnancy Outcome 
 
 IADPSG    International Association of Diabetes and Pregnancy Study  
 
                      Group 
 
 NDDG       National Diabetes Data Group 
 
 FDA           Food and Drug Association 
 
 OGCT       Oral Glucose Challenge Test 
 
 OGTT       Oral Glucose Tolerance Test 
 
 PCOS         PolyCystic Ovarian Syndrome 
 
 FFA          Free Fatty Acid 
 
 VSD         Ventricular Septal Defect 
 
 TGA        Transposition of Great Artery 
 
 IUFD        IntraUterine Fetal Demise 
 
 TOF         Tetrology Of Fallot 
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 NTD        Neural Tube Defect 
 
 RDS        Respiratory Distress Syndrome 
 
 IUGR      IntraUterine Growth Restriction 
 
 LGA        Large for Gestational Age 
 
 NST        Non-Stress Test 
 
 RES        Reticulo Endothelial System 
 
 ARDS     Adult Respiratory Distress Syndrome 
 
 NAFLD  Non-Alcoholic Fatty Liver Disease 
 
 SLE         Systemic Lupus Erythematosis 
 
 RIA          Radio Immune Assay 
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                                 PROFORMA 
 
 
NAME                                                                      AGE:                                    IP / OP NO: 
                                                                                             
ADDRESS: 
 
OBSTETRIC CODE:                                                                                  
 
MARITAL HISTORY:                                                                                        
 
MENSTRUAL HISTORY: 
 
HISTORY OF PRESENTING ILLNESS: 
 
FAMILY HISTORY: 
 
PAST HISTORY: 
 
OBSTETRIC HISTORY:                                                                                         LMP: 
                                                                                                                                     EDD: 
 
           EXAMINATION:                                                                                       HEIGHT: 
                                                                                                                                 WEIGHT: 
                                                                                                                                  BMI:  
 
         INVESTIGATIONS   
                    
 
                   At 16-24 week:  Hb%  , S.ferritin , OGCT      
                                                                                                                                                            
                   At 24-28weeks & 32-34weeks: OGCT,  OGTT (if required) 
           
           
                   USG      
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S.NO NAME AGE BMI OBS.CODE RISK FACTOR GA Hb% S.FERRITIN OGCT -I OGCT-2 OGTT FBS PPBS OUTCOME
1 Vasantha 32 23.3 PRIMI   - 19 11.2 12.2 78 87   -   -   -   -
2 Santha 31 24.5 G2P1L1 PCOS 17 11 16.78 79 98   -   -   -   -
3 Sudha .P 22 21.1 PRIMI   - 23 11.9 15.6 76 123   -   -   -   -
4 Madhavi 24 21.5 PRIMI           - 21 12.1 66.05 152         - 99/185/146/142       -      - GDM-INSULIN
5 Priya .J 28 21.1 PRIMI   - 19 12.3 23.4 123 124   -   -   -   -
6 Gokila 29 23.3 G2P1L1   - 16 11.8 35.8 99 101    -    -   -   -
7 Sumathi 31 20.6 G2A1   - 24 13.1 34.99 88 123    -   -   -   -
8 Sankari 26 23.8 PRIMI   - 23 11.2 15.9 73 99   -   -   -   -
9 Visagam.M 27 26.1 G2P1L1 F/H- DM+ 18 13.6 96.98 152        - 98/192/148/140 140 220 GDM-INSULIN
10 Sundari 28 23.6 PRIMI PCOS 19 12.6 68 99 126            - 132 263 GDM-INSULIN
11 Banu.M 24 23.6 G2P1L1     - 21 11.6 20.5 101 106   - 108 146 GDM-MNT
12 Agilandal.P 29 21.1 PRIMI   - 21 11.9 36.8 125 109   -   -   -   -
13 Mariammal.K 27 20.1 PRIMI   - 23 12.1 37.09 122 100   -   -   -   -
14 Shanaz.M.Z 24 19.8 PRIMI   - 24 11 23.8 65 99   -   -   -   -
15 Faritha bilal 23 23.6 G2P1L1   - 21 11.8 22.9 86 108   -   -   -   -
16 Suganya 34 26.1 G4P1L1A2   - 19 11.2 20.12 87 99   -   -   -   -
17 Mala.D 27 24.1 PRIMI     - 19 12.8 68.45 122 126    - 102 152 GDM-MNT
18 Sundarammal 27 23.6 PRIMI F/H-DM+ 21 12.5 71.11 106 124    - 151 213 GDM-INSULIN
19 Priyalatha 32 21.6 PRIMI F/H-DM+ 22 12.1 19.05 102 122    - 108 142 GDM-MNT
20 Banumathi 24 19.8 G2P1L1   -- 19 11.8 19.99 98 109    -   -    -    -
21 Sheela balu 25 21.1 G2A1   - 23 11.9 17.56 67 107    -    -    -    -
22 Geethapriya 31 22.1 PRIMI   - 23 12.3 12.66 87 99    -    -    -    -
23 Shanthi .L 30 19.9 G3P1L1A1   - 22 13.1 11.45 78 79    -    -    -    -
24 Dhanya.R 24 23.1 PRIMI   - 21 12.1 34.8 66 90    -    -    -    -
25 Malathi.T 34 29.1 G2P1L0 PREV IUFD 19 13.8 99.1 168   - 98/190/178/157    -    - GDM-INSULIN
MASTER CHART
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S.NO NAME AGE BMI OBS.CODE RISK FACTOR GA Hb% S.FERRITIN OGCT -I OGCT-2 OGTT FBS PPBS OUTCOME
26 Eswari 31 22.6 PRIMI   - 23 12.6 71.11 99 123 152 220 GDM-INSULIN
27 Madhu 26 25.1 PRIMI PCOS 19 11.8 31.12 108 141 99/180/162/140    -   - GDM-INSULIN
28 Latha 31 22.2 PRIMI   PCOS 17 11 16.8 92 123   -   -   -   -
29 Poongothai 21 22.9 G2A1   - 18 12.5 19.9 98 102   -   -   -   -
30 Malar 23 21.7 G2P1L1   - 19 11.5 17.8 99 100   -    -   -   -
31 Mala.P 24 22.7 PRIMI   - 21 11.6 18.6 109 127   -   -   -   -
32 Lavanya 29 23.9 PRIMI   - 22 11.7 67.8 87 124   -   -   -   -
33 Kalaiyarasi 29 24.1 PRIMI F/H-DM+ 22 13.9 99.9 122 186 116/186/163/146   -   - GDM-INSULIN
34 Sumi 30 22.8 G2P1L1   - 16 11.1 26.7 103 124   -   -   -   -
35 Pavithra 31 21.9 PRIMI   - 18 11.9 29.1 107 127   -   -   -   -
36 Zabeen 33 26.3 G3A2 PCOS 23 12.8 70.5 149   - 108/192/196/152   -   - GDM-INSULIN
37 Thilaga 26 24.9 PRIMI PCOS 22 11.6 36.36 106 108   - 100 160 GDM-MNT
38 Bharathi 22 20.1 PRIMI   - 19 11.6 29.4 97 79   -   -   -   -
39 Thamarai 27 19.9 PRIMI   - 22 12.1 22.3 68 99   -   -   -   -
40 Geetha.C 26 22.9 PRIMI   - 21 11.9 15.6 78 123   -   -   -   -
41 Durga 33 22.7 G4A3 BOH 18 13.9 91 106 194 102/200/190/152   -   - GDM-INSULIN
42 Fathiza 21 24.5 PRIMI   - 16 11.2 19.9 102 127   -   -   -   -
43 Gunasundari 24 23.7 G1P1L1   - 17 12 17.65 112 119   -   -   -   -
44 Komala 29 22.3 G3P1L1A1   - 18 12.4 19.63 67 89   -  -   -   -
45 Kiruthiga 27 21.1 G2A1 PCOS 23 11.7 31.7 126 123   -   -   -   -
46 Pushpa 31 21.1 PRIMI F/H-DM+ 19 12.6 39.8 92 99   - 106 152 GDM-MNT
47 Swetharani 26 23.4 PRIMI   - 19 12.7 63.47 106 108   - 156 200 GDM-INSULIN
48 Janani 25 22.6 G2P1L1 F/H-DM+ 21 11.8 31.2 92 86   - 100 146 GDM-MNT
49 Roopa 29 23.7 PRIMI   - 21 12.6 27.8 107 102   -   -   -   -
50 Suruthi 28 24.3 G2P1L1   - 22 12.2 29.7 127 112   -   -   -   - 
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51 Vaseelabanu 27 23.3 PRIMI   - 22 12.4 71.7 74 96   - 136 199 GDM-INSULIN
52 Priya.s 23 23.2 PRIMI   - 23 11.5 15.7 99 122   -   -   -   -
53 Jayanthi 25 22.6 PRIMI   - 21 11.2 17.9 65 103   -   -   -   -
54 Mirnalini 26 24.1 G2P1L1   - 22 11 68.2 78 97   -   -   -   -
55 Wahitha 24 23.6 PRIMI   - 19 13.9 91.99 102 153 89/199/158/146   -   - GDM-MNT
56 subbulaxmi 27 24.4 G2P1L1 prev big baby 23 12.7 61.47 106 199 106/192/190/152   -   - GDM-INSULIN
57 Sangetha 24 23.3 PRIMI   - 24 11.9 31.34 112 125   -   -   -   -
58 Sathya 26 23.4 PRIMI   - 17 11.2 23.78 101 119   -   -   -   -
59 Punitha 29 22.7 G2P1L1   - 18 11.9 34.67 87 125   -   -   -   -
60 Hemalatha 29 21.2 G2P1L1   - 22 11.8 36.39 111 108   - 96 149 GDM-MNT
61 Muthumari 28 23.3 PRIMI   - 19 11.9 19.65 99 111   -   -   -   -
62 Palaniyamma 33 22.9 PRIMI   - 16 12 67.6 94 121   -   -   -   -
63 Suguna 31 22.9 PRIMI   - 18 12.5 34.56 92 125   -   -   -   -
64 Sindhu 27 23.9 G2P1L1   - 23 11 29.5 101 119   -   -   -   -
65 Priyanka 29 26.3 PRIMI   - 22 12.6 66.54 119 143 92/143/166/119  -    - GDM-MNT
66 Suganthi 26 26.4 PRIMI PCOS 21 12.5 64.88 121 117   - 146 199 GDM-INSULIN
67 Laxmi 31 19.7 PRIMI   - 22 11.4 19.34 120 123   -   -   -   -
68 Saraswathi 29 19.8 PRIMI   - 22 11.7 28.68 123 124   -   -   -   -
69 Poongodi 30 21.2 G2P1L1   - 22 12.1 24.87 101 109   -   -   -   -
70 Vasumathi 29 22.1 G2P1L1 prev big baby 23 12.4 23.89 99 106   - 99 194 GDM-INSULIN
71 Rangammal 30 21.7 PRIMI   - 19 13.1 33.57 87 99   -   -   -   -
72 Jeevitha 26 22.3 G2P1L1   - 18 11.9 21.21 85 96   -   -   -   -
73 Panjalai 27 22.9 PRIMI   - 22 12.4 17.1 89 94   -   -   -   -
74 Meena 27 23.9 G2P1L1 F/H-DM1+ 23 12.6 61.11 66 106   - 129 230 GDM-INSULIN
75 Nagadevi 33 24.1 PRIMI F/H-DM1+ 21 13.1 31.26 106 152 99/180/150/106   -   - GDM-MNT
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76 Sumathi 21 25.3 PRIMI PCOS 22 12.9 66.89 66 106   - 140 199 GDM-INSULIN
77 Sankari 22 22.4 PRIMI   - 19 11.8 23.3 87 89   -   -   -   -
78 Visagam.M 24 25.6 G2P1L1 prev big baby 18 12.8 71.23 71 123   - 111 163 GDM-MNT
79 Sundari 24 23.1 PRIMI   - 19 12.1 32.34 103 116   - 102 156 GDM-MNT
80 Banu.M 34 24.3 G2P1L1 Prev GDM 23 11.7 21.67 106 192 106/180/170/140   -   - GDM-INSULIN
81 Agilandal.P 24 22.2 PRIMI    - 18 12.3 61.8 88 94   -   -   -   -
82 Mariammal.K 25 18.7 PRIMI   - 19 11.8 33.8 98 104   -   -   -   -
83 Shanaz.M.Z 36 27.4 G3P2L2 prev big baby 21 13.4 91.99 152   - 97/180/171/132   -   - GDM-INSULIN
84 Nalini 35 26.1 G2P1L1 prev GDM 22 12.9 69 106 199 100/180/170/142   -   - GDM-INSULUN
85 Eswari 31 19.7 PRIMI   - 18 11.1 13.5 99 102   -   -   -   -
86 Thamarai 25 22.6 PRIMI   - 16 12 18.5 67 89   -   -   -   -
87 Geetha.C 24 22.3 PRIMI   - 22 12.2 13.9 88 92   -   -   -   -
88 Durga 29 26.3 PRIMI PCOS 23 12.8 82.23 84 118   - 108 156 GDM-MNT
89 Fathiza 29 21.1 G2P1L1  - 23 12.3 33.4 119 108   - 99 161 GDM-MNT
90 Gunasundari 26 23.8 PRIMI   - 23 11.5 25.5 100 124   -   -   -   -
91 Komala 27 21.3 G2P1L1   - 22 11.7 29.9 120 101   -   -   -   -
92 Kiruthiga 22 22.7 PRIMI   - 19 12.9 31.8 107 112   -   -   -   -
93 Pushpa 21 22.5 PRIMI   - 21 12.6 25.9 94 99   -   -   -   -
94 Janani 27 22.9 G2P1L1 F/H-DM+ 20 12.9 81.22 99 162 98/182/180/142   -   - GDM-INSULIN
95 Surya 23 21.1 G2P1L1   - 20 12.5 22.9 95 106   -   -   -   -
96 Kalaiselvi 35 20.7 PRIMI   - 20 12.8 36.8 88 109   -   -   -   -
97 Uma.A 24 19.3 PRIMI   - 21 12.9 39.7 89 114   -   -   -   -
98 Vidhya 23 18.4 G2P1L1   - 22 11.2 45.6 106 108   -   -   -   -
99 Muniyammal 31 22.8 PRIMI PCOS 23 12.6 72.6 96 108   - 142 262 GDM-INSULIN
100 Mageswari 26 24.1 PRIMI   - 21 12.4 39.7 104 106   - 84 156 GDM-MNT
MASTER CHART
 
 
 
 
 
 
 
 
 
 
 
 
     
101 
 
               CERTIFICATE OF APPROVAL  
 
                                  
 
102 
 
              PATIENT CONSENT FORM 
 
 
Title: ASSOCIATION OF ELEVATED SERUM FERRITIN  LEVELS IN MID-
PREGNANCY AND THE RISK  OF GESTATIONAL DIABETES MELLITUS”   
 
Name of the Investigator : Dr. T.Rajatharangani 
Name of the Participant : 
Name of the Institution : IOG, Egmore, Chennai-8. 
 
I am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in this study. I was free to ask any questions and they 
have been answered. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have informed the investigator of all the treatments I am taking or have taken in the past 
months/years including any native (alternative) treatments. 
6. I have been advised about the risks associated with my participation in the study.* 
7. I have not participated in any research study within the past ____ month(s). * 
8. I am aware of the fact that I can opt out of the study at any time without having to give 
any reasoned this will not affect my future treatment in this hospital. * 
9. I am also aware that the investigators may terminate my participation in the study at any 
time, for any reason, without my consent. * 
10. I hereby give permission to the investigators to release the information obtained from me 
as result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, 
and IEC if required. 
11. I understand that my identity will be kept confidential if my data are publicly 
presented. 
12. I have had my questions answered to my satisfaction. 
13. I consent voluntarily to participate in the research/study. 
I am aware that if I have any question during this study, I should contact theinvestigator. By 
signing this consent form, I attest that the information given in this document has been clearly 
explained to me and understood by me. I will be given a copy of this consent document. 
 
 
 
                  
  
                                                                           
 
 
 
                                                                                               Signature/thumb imp of the patient 
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